[October 29, 2025] — ALK Positive, the leading patient-founded nonprofit dedicated to accelerating research and improving outcomes for people living with ALK-positive lung cancer, today announced the expansion of Dr. Ken Culver’s role with the organization, appointing him Executive Director and Medical Director.
Dr. Culver, a physician-scientist and accomplished research leader, brings deep expertise in oncology, drug development, and nonprofit leadership. In this dual role, he will guide ALK Positive’s strategic direction, oversee its expanding research investment portfolio, and strengthen partnerships across academia, industry, and the global patient community.
“After more than three years as our Director of Research & Clinical Affair, Dr. Culver’s new role marks an exciting milestone for ALK Positive,” said Kirk Smith, president of the Board of Directors. “His scientific acumen, integrity, and dedication to patient-centered research make him the ideal leader to advance our mission and expand our impact. He also has a proven leadership style that is grounded in empathy, authenticity, and a deep connection to the patient and caregiver experience.
Dr. Culver previously served as ALK Positive’s Director of Research & Clinical Affairs, leading the organization’s various Medical Committees, scientific review and grantmaking programs and helping establish collaborations with leading cancer centers worldwide. Earlier in his career, he held senior positions in drug development and clinical research, contributing to the development of novel therapies in oncology and precision medicine.
“I am honored to serve this remarkable community and to continue building on ALK Positive’s legacy of patient-driven science,” said Dr. Culver. “Our members are changing the face of cancer research. Together, we will continue to accelerate discovery and bring new hope to people living with ALK-positive lung cancer.”
Since its founding in 2017, ALK Positive Inc. has become one of the most impactful patient-led research organizations in oncology—funding more than $10 million in scientific grants and clinical trials, supporting translational studies in ALK resistance and minimal residual disease (MRD), and partnering with leading investigators around the world. The organization’s mission-driven approach empowers patients to play an active role in shaping research priorities and advancing access to innovative treatments.
About ALK Positive ALK Positive is a 501(c)(3) nonprofit organization created by and for patients and caregivers affected by ALK-positive lung cancer. The organization’s mission is to seek a cure for ALK positive cancer, and to improve patients’ quality of life and life expectancy worldwide. Through strategic research funding, education, and global advocacy, ALK Positive is transforming the future of targeted cancer therapy. Learn more at: www.alkpositive.org
